ASTRAZENECA COMPLETES AGREEMENT WITH PERRIGO FOR RIGHTS TO ENTOCORT® IN THE US AstraZeneca today announced that it has completed its agreement with Perrigo Company plc for the divestment of US rights to Entocort® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn's disease, an area of medicine outside AstraZeneca's strategic focus. Upon completion of the agreement, Perrigo paid AstraZeneca $380 million to acquire the rights to sell Entocort capsules and the authorised generic Entocort capsules marketed by Par Pharmaceuticals. The transaction does not include the transfer of any AstraZeneca employees or facilities. The agreement completes the global divestment of Entocort, following the agreement entered into in July 2015 with Tillotts Pharma AG, part of the Zeria Group, for the divestment of global rights to Entocort outside the US. The divestment further emphasises AstraZeneca's strategic focus on three main therapy areas. The transaction does not impact AstraZeneca's financial guidance for 2015. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Esra Erkal-Paler UK/Global +44 20 7604 8030 Neil Burrows UK/Global +44 20 7604 8032 Vanessa Rhodes UK/Global +44 20 7604 8037 Karen Birmingham UK/Global +44 20 7604 8120 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Enquiries UK Thomas Kudsk Larsen Oncology +44 7818 524185 Eugenia Litz RIA +44 7884 735627 Nick Stone CVMD +44 7717 618834 Craig Marks Finance +44 7881 615764 Christer Gruvris Consensus Forecasts +44 7827 836825 US Lindsey Trickett Oncology, ING +1 240 543 7970 Mitch Chan Oncology +1 240 477 3771 Dial / Toll-Free +1 866 381 7277 Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal 15 December 2015 -ENDS-
AZ COMPLETES AGREEMENT WITH PERRIGO ASTRAZENECA COMPLETES
Top 10 Most Recent News Articles
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event
Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...
Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations
Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...
Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign
A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...
Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard
A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...
Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm
A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...
Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation
The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...
Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC
Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...
Continue Reading
Community in Shock After Fatal Bakersfield Shooting
The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...
Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study
Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...
Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026
LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...
Continue ReadingTop 5 Most Recently Viewed Articles
Emerie.ai: Transforming Customer Experience in FinTech
Introducing Emerie.ai Emerie.ai, formerly known as ENACOMM Financial Services, Inc., represents a significant step forward in the FinTech arena. The company has undergone a rebranding to better reflect its core offering—an Intelligent Virtual Assistant (IVA)—which utilizes cutting-edge artificial intelligence technology. As customer service standards continue to rise,...
Continue Reading
Explore the Groundbreaking JumpCloudLand Conference 2026
JumpCloudLand Conference: A New Era for IT Professionals JumpCloud Inc. has launched a remarkable initiative—JumpCloudLand, a comprehensive virtual conference tailored for IT professionals. This dynamic event is set to take place on February 10, 2026, providing a unique opportunity for IT leaders globally to gather and enhance their skills. The nature of IT is...
Continue Reading
General Shale Introduces an Innovative Brick Collection for 2026
Innovative Brick Collection from General Shale for 2026 Transforming Spaces with Stylish Brick Designs For years, clay brick has symbolized durability and tradition. General Shale is now revolutionizing brickwork by introducing a new collection that transforms brick into a modern art form, showcasing a range of sizes, textures, and colors. Their contemporary lineup...
Continue Reading
Revolutionary Breakthrough in Gene Therapy for SCN2A Disorders
Groundbreaking Research at UCSF Offers New Hope The laboratories led by Dr. Kevin Bender and Dr. Nadav Ahituv have made significant strides in gene therapy through groundbreaking research. Their recent study unveils a compelling new approach to address SCN2A haploinsufficiency, a critical factor linked to various neurodevelopmental disorders and early-onset epilepsy. This...
Continue Reading
FirstEnergy's New Leadership: Brian Tierney Takes Charge
FirstEnergy Corporation Welcomes Brian Tierney as Chair FirstEnergy Corp. (NYSE: FE) has announced the appointment of its President and Chief Executive Officer, Brian X. Tierney, as the new Chair of the Board. This change takes effect on a future date, bringing fresh leadership to the company valued at $22.6 billion. Tierney, who has been in the role of President and CEO...
Continue Reading